GlobeNewswire Inc.··Amphista TherapeuticsAmphista Therapeutics Showcases Next-Gen Cancer Degraders at AACR Meeting
Amphista Therapeutics presents three programs at AACR 2026, including oral presentation on AMX-883 BRD9 degrader for AML treatment.
LLYNVScancer treatmentprotein degradation